ENDOLEASE

• Systemic Toxicity: Even modern drugs affect healthy organs and cause off-target on tissue effects while trying to treat diseased tissue.
• Limited Efficacy: Therapeutic concentrations often do not reach target tissues and even targeted therapies are constrained by systemic exposure.
• Barrier to Innovation: Many promising compounds fail early due to safety limitations.

These challenges are particularly critical in cancer, cardiovascular, and neurological diseases—the leading causes of death worldwide—highlighting the urgent need for therapies that act precisely where they’re needed.

ENDOLEASE is a device-driven innovation enabling targeted, continuous drug release directly into the artery supplying the target tissue—maximizing local efficacy while minimizing systemic side effects.

• Minimally Invasive Implantation: Delivered via catheter, the implant can be placed in any vital artery.
• Intra-Arterial Delivery: The implant releases drugs directly into the supplying artery, ensuring precise, sustained therapy exactly where it’s needed, and is fully bioresorbed subsequently.
• Enhanced Efficacy & Safety: Localized delivery increases therapeutic effect while minimizing systemic exposure and side effects.

ENDOLEASE delivers drugs directly into the downstream capillary network of target tissue, unlike conventional drug-eluting stents that primarily act mechanically and release drugs into the artery wall.

Unlike stents, ENDOLEASE delivers drugs into the tissue’s downstream capillaries, allowing:

• delivery of significantly higher drug doses
• release of complex molecules such as antibodies
• highly controlled, localized therapy of multiple simultaneous drugs.

ENDOLEASE is a modular, implantable platform that combines a fundamentally new IP protected delivery principle with the flexibility to adapt to multiple drug classes and therapeutic areas, positioning it as a disruptive innovation in precision medicine.